-
公开(公告)号：US11738010B2
公开(公告)日：2023-08-29
申请号：US17385258
申请日：2021-07-26
Applicant: MERCK SHARP & DOHME CORP.
Inventor： John P. Caldwell , Reynalda De Jesus , Fa-Xiang Ding , Charles J. Gill , Ginny Dai Ho , Sookhee N. Ha , Sandra J. Koseoglu , Marc A. Labroli , Sang Ho Lee , Christina Madsen-Duggan , Mihir Mandal , Terry Roemer , Jing Su , Christopher Michael Tan , Zheng Tan , Haifeng Tang , Hao Wang , Christine Yang , Shu-Wei Yang
IPC: A61K31/4439 , A61P31/04 , A61K31/407 , A61K31/421 , A61K31/422 , A61K31/427 , A61K31/431 , A61K31/4375 , A61K31/438 , A61K31/4709 , A61K31/5377 , A61K31/5383 , C07D263/26 , C07D413/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D491/048 , C07D495/04 , C07D498/04
CPC classification number: A61K31/4439 , A61K31/407 , A61K31/421 , A61K31/422 , A61K31/427 , A61K31/431 , A61K31/438 , A61K31/4375 , A61K31/4709 , A61K31/5377 , A61K31/5383 , A61P31/04 , C07D263/26 , C07D413/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D491/048 , C07D495/04 , C07D498/04
Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.
-
公开(公告)号：US11141403B2
公开(公告)日：2021-10-12
申请号：US16061481
申请日：2016-12-13
Applicant: MERCK SHARP & DOHME CORP. , John P. Caldwell , Ginny Dai Ho , Sookhee N. Ha , Sandra J. Koseoglu , Marc A. Labroli , Sang Ho Lee , Christina Madsen-Duggan , Mihir Mandal , Jianping Pan , Weidong Pan , Terry Roemer , Jing Su , Christopher Michael Tan , Zheng Tan , Hao Wang , Christine Yang , Shu-Wei Yang
Inventor： John P. Caldwell , Ginny Dai Ho , Sookhee N. Ha , Sandra J. Koseoglu , Marc A. Labroli , Sang Ho Lee , Christina Madsen-Duggan , Mihir Mandal , Jianping Pan , Weidong Pan , Terry Roemer , Jing Su , Christopher Michael Tan , Zheng Tan , Hao Wang , Christine Yang , Shu-Wei Yang
IPC: A61K31/397 , A61P31/04 , A61K31/407 , C07D235/08 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/06 , C07D471/04
Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.
-
公开(公告)号：US20210061777A1
公开(公告)日：2021-03-04
申请号：US17093833
申请日：2020-11-10
Applicant: Merck Sharp & Dohme Corp.
Inventor： Mihir B. Mandal , David B. Olsen , Jing Su , Lihu Yang , Katherine Young , Takao Suzuki , Lanying You
IPC: C07D263/20 , C07D413/14 , A61K31/421 , A61K31/422 , C07D413/10 , A61K45/06 , A61K31/427 , A61K31/4439 , A61K31/541 , C07D413/06 , C07D417/10 , C07D471/04 , C07D487/04 , A61K31/437 , A61K31/4985 , A61K31/506 , A61K31/5377 , A61K31/553 , C07D413/04 , C07D417/14
Abstract: The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.
-
公开(公告)号：US10752621B2
公开(公告)日：2020-08-25
申请号：US16490958
申请日：2018-03-15
Applicant: Merck Sharp & Dohme Corp.
Inventor： Jing Su , Lihu Yang , Takao Suzuki
IPC: C07D413/14 , C07D263/22 , C07D413/10 , C07D417/14 , A61P31/06 , A61K9/00
Abstract: The present invention relates to oxazolidinone Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.
-
公开(公告)号：US09708336B2
公开(公告)日：2017-07-18
申请号：US15110431
申请日：2015-01-16
Applicant: Merck Sharp & Dohme Corp.
Inventor： Mihir Mandal , Haifeng Tang , Li Xiao , Jing Su , Guoqing Li , Shu-Wei Yang , Weidong Pan , Haiqun Tang , Reynalda DeJesus , Jacqueline Hicks , Matthew Lombardo , Hong Chu , William Hagmann , Alex Pasternak , Xin Gu , Jinlong Jiang , Shuzhi Dong , Fa-Xiang Ding , Clare London , Dipshikha Biswas , Katherine Young , David N. Hunter , Zhiqiang Zhao , Dexi Yang
IPC: C07D491/048 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/5025 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K45/06 , C07D401/04 , C07D409/10 , C07D487/04 , C07D471/10 , C07D471/04 , C07D451/04 , C07D417/14 , C07D417/10 , C07D413/10 , C07D401/14 , C07D405/12 , C07D405/10 , C07D403/10 , C07D401/10 , C07D413/14 , C07D405/14 , A61K31/41 , C07D257/04 , A61K31/197 , A61K31/407 , A61K31/4155 , A61K31/4178 , A61K31/4192 , A61K31/422 , A61K31/4245 , A61K31/427
CPC classification number: C07D491/048 , A61K31/197 , A61K31/407 , A61K31/41 , A61K31/4155 , A61K31/4178 , A61K31/4192 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/5025 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K45/06 , C07D257/04 , C07D401/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/10 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D451/04 , C07D471/04 , C07D471/10 , C07D487/04 , Y02A50/473 , A61K2300/00
Abstract: The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.
-
Patent Agency Ranking
公开(公告)号：US11752128B2
公开(公告)日：2023-09-12
申请号：US17385194
申请日：2021-07-26
Applicant: MERCK SHARP & DOHME CORP.
Inventor： John P. Caldwell , Ginny Dai Ho , Sookhee N. Ha , Sandra J. Koseoglu , Marc A. Labroli , Sang Ho Lee , Christina Madsen-Duggan , Mihir Mandal , Jianping Pan , Weidong Pan , Terry Roemer , Jing Su , Christopher Michael Tan , Zheng Tan , Hao Wang , Christine Yang , Shu-Wei Yang
IPC: A61K31/397 , A61P31/04 , A61K31/407 , C07D235/08 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/06 , C07D471/04
CPC classification number: A61K31/397 , A61K31/407 , A61P31/04 , C07D235/08 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/06 , C07D471/04
Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.
-
公开(公告)号：US20180290987A1
公开(公告)日：2018-10-11
申请号：US15766395
申请日：2016-10-17
Applicant: Mihir B. MANDAL , David B. OLSEN , Jing SU , Lihu YANG , Katherine YOUNG , Takao SUZUKI , Lanying YOU , Merck Sharp & Dohme Corp.
Inventor： Mihir B. Mandal , David B. Olsen , Jing Su , Lihu Yang , Katherine Young , Takao Suzuki , Lanying You
IPC: C07D263/20 , C07D471/04 , C07D413/10 , C07D417/10 , C07D413/04 , C07D487/04 , C07D413/06 , C07D417/14 , C07D413/14 , A61K31/421 , A61K31/437 , A61K31/422 , A61K31/427 , A61K31/4439 , A61K31/506 , A61K31/553 , A61K31/4985 , A61K31/541 , A61K31/5377 , A61K45/06
Abstract: The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.
-
公开(公告)号：US20180186808A1
公开(公告)日：2018-07-05
申请号：US15910571
申请日：2018-03-02
Applicant: Merck Sharp & Dohme Corp.
Inventor： Katherine Young , David B. Olsen , Sheo B. Singh , Jing Su , Robert R. Wilkening , James M. Apgar , Dongfang Meng , Dann Parker , Mihir Mandal , Lihu Yang , Ronald E. Painter , Qun Dang , Takao Suzuki
IPC: C07D493/08 , C07F7/18 , C07C53/18 , C07C309/06 , C07D493/18
CPC classification number: C07D493/08 , C07C53/18 , C07C309/06 , C07D493/18 , C07D519/00 , C07F7/1804
Abstract: The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.
-
公开(公告)号：US20160333021A1
公开(公告)日：2016-11-17
申请号：US15110431
申请日：2015-01-16
Applicant: Merck Sharp & Dohme Corp.
Inventor： Mihir Mandal , Haifeng Tang , Li Xiao , Jing Su , Guoqing Li , Shu-Wei Yang , Weidong Pan , Haiqun Tang , Reynalda DeJesus , Jacqueline Hicks , Matthew Lombardo , Hong Chu , William Hagmann , Alex Pasternak , Xin Gu , Jinlong Jiang , Shuzhi Dong , Fa-Xiang Ding , Clare London , Dipshikha Biswas , Katherine Young , David N. Hunter , Zhiqiang Zhao , Dexi Yang
IPC: C07D491/048 , A61K31/41 , A61K45/06 , A61K31/407 , A61K31/197 , C07D405/12 , A61K31/5377 , C07D403/10 , A61K31/4192 , A61K31/496 , C07D401/10 , A61K31/454 , A61K31/4439 , C07D409/10 , C07D417/10 , A61K31/427 , C07D405/14 , C07D413/10 , A61K31/422 , A61K31/506 , A61K31/497 , A61K31/4178 , A61K31/501 , A61K31/4155 , C07D471/04 , A61K31/437 , C07D417/14 , C07D401/14 , C07D487/04 , A61K31/5025 , A61K31/4245 , A61K31/541 , C07D401/04 , C07D413/14 , A61K31/55 , C07D471/10 , C07D257/04
CPC classification number: C07D491/048 , A61K31/197 , A61K31/407 , A61K31/41 , A61K31/4155 , A61K31/4178 , A61K31/4192 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/5025 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K45/06 , C07D257/04 , C07D401/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/10 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D451/04 , C07D471/04 , C07D471/10 , C07D487/04 , Y02A50/473 , A61K2300/00
Abstract: The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.
-
公开(公告)号：US20220259188A1
公开(公告)日：2022-08-18
申请号：US17614732
申请日：2020-06-01
Applicant: Hua ZHOU , John J. ACTON, III , Michael J. ARDOLINO , Yi-Heng CHEN , Peter H. FULLER , Anmol GULATI , Rebecca Elizabeth JOHNSON , William P. KAPLAN , Solomon D. KATTAR , Mitchell H. KEYLOR , Derun LI , Kaitlyn Marie LOGAN , Min LU , Gregori J. MORRIELLO , Santhosh F. NEELAMKAVIL , Barbara PIO , Nunzio SCIAMMETTA , Vladimir SIMOV , Jing SU , Luis TORRES , Xin YAN , Merck Sharp & Dohme Corp.
Inventor： Hua Zhou , John J. Acton, III , Michael J. Ardolino , Yi-Heng Chen , Peter H. Fuller , Anmol Gulati , Rebecca Elizabeth Johnson , William P. Kaplan , Solomon D. Kattar , Mitchell H. Keylor , Derun Li , Kaitlyn Marie Logan , Min Lu , Gregori J. Morriello , Santhosh F. Neelamkavil , Barbara Pio , Nunzio Sciammetta , Vladimir Simov , Jing Su , Luis Torres , Xin Yan
IPC: C07D405/14 , C07D487/08 , C07D409/14 , C07D403/04 , C07D403/14 , C07D498/04 , C07D498/08 , C07D487/10 , C07D401/14 , C07D471/10 , C07D491/107 , C07D471/04 , C07D487/04 , A61P25/16
Abstract: The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.033 seconds)
